University of Messina

NDA Partners Appoints Senior Global Regulatory Affairs Executive, Dr. Daniela Drago as Partner in the Firm

Retrieved on: 
Tuesday, April 4, 2023
CSL Vifor, RAPS, Medical school, Swiss Federal Institute of Technology, Swiss, Biozentrum University of Basel, University, Gene, Swiss Federal Institute of Aquatic Science and Technology, ETH, Biogen, CMC, Roche, George Washington University Hospital, Bausch, Regulatory science, History, Doctor of Philosophy, Associate, Bausch & Lomb, ECPM, MS, FRAPS, Partner, UCSF, Ophthalmology, School, Cell, Executive Committee, Drug development, American Society of Gene and Cell Therapy, University of Messina, Regulatory affairs, George Washington University, Neurology, Pharmaceutical medicine, Society, Pharmaceutical industry, Medicine, Chemistry

WASHINGTON, April 4, 2023 /PRNewswire-PRWeb/ -- NDA Partners' Vice President and General Manager, Eric Fish, announced today that Dr. Daniela Drago, a senior global regulatory affairs executive, has been appointed as Partner in the firm. Dr. Drago first worked as an Expert Consultant with NDA Partners in 2014 and formerly held senior global regulatory and medical affairs positions at Biogen, Roche, Vifor Pharma, Reckitt Benckiser, Aurion Biotech, and Bausch & Lomb.

Key Points: 
  • NDA Partners' Vice President and General Manager, Eric Fish, announced today that Dr. Daniela Drago, a senior global regulatory affairs executive, has been appointed as Partner in the firm.
  • Dr. Drago first worked as an Expert Consultant with NDA Partners in 2014 and formerly held senior global regulatory and medical affairs positions at Biogen, Roche, Vifor Pharma, Reckitt Benckiser, Aurion Biotech, and Bausch & Lomb.
  • WASHINGTON, April 4, 2023 /PRNewswire-PRWeb/ -- NDA Partners' Vice President and General Manager, Eric Fish, announced today that Dr. Daniela Drago , a senior global regulatory affairs executive, has been appointed as Partner in the firm.
  • Dr. Drago is a CMC and global regulatory affairs executive with a history of accomplishments spanning pharmaceutical, biotech, and academic roles.

Sintalica Bioscience Announces Key Approval Milestones from the Italian Health Authority

Retrieved on: 
Wednesday, November 23, 2022
Science, Neurology, Research, Alternative Medicine, Health, University, Education, Clinical Trials, Inflammation, Neurodegeneration, Biotechnology, Chemistry, Partnership, Laboratory, Entrepreneurship, University of Messina, Pharmacology, Research, Safety, Spinal cord injury, University, Tryptamine, Patient, Pharmaceutical industry, Fine chemical, Fibromyalgia, Psilocybin

Sintalicas research and drug development program is focused on neurodegenerative disorders, including SCI-Induced Chronic Neuropathic Pain (Spinal Cord Injury), Fibromyalgia, and Inflammation.

Key Points: 
  • Sintalicas research and drug development program is focused on neurodegenerative disorders, including SCI-Induced Chronic Neuropathic Pain (Spinal Cord Injury), Fibromyalgia, and Inflammation.
  • Sintalica has filed three provisional patents for proprietary psychedelic molecules with claims of improved stability, efficacy and bioavailability.
  • Sintalica has an exclusive research partnership with leading Italian research institutes, including the University of Messina and the University of Niccol Cusano of Rome.
  • Sintalica Bioscience Corp. is a Canadian drug discovery company operating through its Italian subsidiary focused on using psychedelics to create breakthrough treatments for neuroinflammatory disorders.

Senior Global Regulatory Affairs Executive, Dr. Daniela Drago, Joins NDA Partners as Expert Consultant

Retrieved on: 
Wednesday, September 7, 2022
Swiss Federal Institute of Technology, University, Pharmaceutical medicine, Swiss, Pharmacokinetics, Ophthalmology, Program, Gene, Cell, ETH, Executive Committee, Biogen, Doctor of Philosophy, Associate, Bausch & Lomb, Medical school, American Society of Gene and Cell Therapy, Society, Bausch, University of Messina, Swiss Federal Institute of Aquatic Science and Technology, ECPM, Biozentrum University of Basel, CMC, School, Drug development, Neurology, Roche, Regulatory science, George Washington University, History, George Washington University School of Medicine & Health Sciences, Biotechnology, Regulatory affairs, University of California, San Francisco, UCSF, Toxicology, MS, RAPS, Vifor Pharma, USP, FRAPS, General manager, Medical device, Pharmaceutical industry, Medicine, Chemistry

WASHINGTON, Sept. 7, 2022 /PRNewswire-PRWeb/ -- NDA Partners' General Manager, Eric Fish, announced today that Dr. Daniela Drago, a senior global regulatory affairs executive, has joined the firm as an Expert Consultant. Dr. Drago is a regulatory affairs executive with a history of accomplishments spanning pharmaceutical, biotech, and academic roles. She has held senior global regulatory and medical affairs positions at Biogen, Roche, Vifor Pharma, Reckitt Benckiser, Aurion Biotech, and Bausch & Lomb. She was formerly an Associate Professor at George Washington University's School of Medicine where she redesigned and led the regulatory affairs program. Currently, she is an Adjunct Faculty for the University of California, San Francisco (UCSF), American Course on Drug Development and Regulatory Sciences (ACDRS), and the University of Basel, European Center of Pharmaceutical Medicine (ECPM).

Key Points: 
  • NDA Partners' General Manager, Eric Fish, announced today that Dr. Daniela Drago, a senior global regulatory affairs executive, has joined the firm as an Expert Consultant.
  • Dr. Drago has held senior global regulatory and medical affairs positions at Biogen, Roche, Vifor Pharma, Reckitt Benckiser, Aurion Biotech, and Bausch & Lomb.
  • WASHINGTON, Sept. 7, 2022 /PRNewswire-PRWeb/ -- NDA Partners' General Manager, Eric Fish, announced today that Dr. Daniela Drago , a senior global regulatory affairs executive, has joined the firm as an Expert Consultant.
  • She has held senior global regulatory and medical affairs positions at Biogen, Roche, Vifor Pharma, Reckitt Benckiser, Aurion Biotech, and Bausch & Lomb.

Nemysis Ltd Announces Appointment of Antonino Santoro as Adviser for Scientific Affairs

Retrieved on: 
Monday, February 7, 2022
LTD, GLOBE, Business, E40, Epitope, Committee on Herbal Medicinal Products, Dietary supplement, Worldwide, Trypsin, Cosmetics, Association, Safety, European Institute of Peace, Knowledge, Antonino, University, Federalisation of the European Union, Anemia, Hotel manager, University of Messina, Nutraceutical, Gluten-sensitive enteropathy–associated conditions, S.P. Tre Penne, Italian Association of Environmental and Resource Economists (IAERE), Head, Regulatory affairs, Nutrient deficiency, Institutions of the European Union, Chemist

DUBLIN, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Nemysis Ltd today announces the appointment of Antonino Santoro to its Executive Team as Adviser forScientific Affairs.

Key Points: 
  • DUBLIN, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Nemysis Ltd today announces the appointment of Antonino Santoro to its Executive Team as Adviser forScientific Affairs.
  • Antonino Santoro is a Chemist, graduate of the University of Messina, Italy, with over 30 years of experience in Regulatory Affairs and a strong expertise in the development of Prescription and Nutraceutical products.
  • Currently, Antonino serves as a board member of Sifi S.p.A, Glycemicon AG and Difass International S.r.l.
  • "We are very honoured and privileged to have established this long-term collaboration with such an expert on Regulatory Affairs", said Danilo Casadei-Massari, Chairman of the Board.

Daniela Drago Joins Aurion Biotech as Chief Regulatory Officer

Retrieved on: 
Tuesday, August 10, 2021
Stem Cells, Biotechnology, Pharmaceutical, Optical, Surgery, Health, Genetics, Other Health, Hoffmann-La Roche, George Washington, Kyoto, Severe cognitive impairment, Patient, Kyoto Prefectural University of Medicine, Swiss Federal Institute of Aquatic Science and Technology, Research, Swiss Federal Institute of Technology, Visual acuity, RAC, Multimedia, Ophthalmology, Vifor Pharma, Regenerative medicine, Toyota Aurion, Swiss, University of Messina, Leadership, Cell, American Society of Gene and Cell Therapy, Bausch & Lomb, Time, Society, ETH Zurich, GWU, Drug development, Biotechnology, University, Gene, Doctor of Philosophy, Medical device, Pharmaceutical industry

Aurion Biotech , whose mission is to cure blindness by developing a differentiated platform of advanced therapies to treat ocular diseases, today announced it has appointed Daniela Drago, MS, PhD, RAC, as chief regulatory officer.

Key Points: 
  • Aurion Biotech , whose mission is to cure blindness by developing a differentiated platform of advanced therapies to treat ocular diseases, today announced it has appointed Daniela Drago, MS, PhD, RAC, as chief regulatory officer.
  • View the full release here: https://www.businesswire.com/news/home/20210810005233/en/
    Daniela Drago, Aurion Biotech Chief Regulatory Officer (Photo: Business Wire)
    A natural-born leader, Daniela brings to Aurion Biotech both broad and deep insights - not only in ophthalmology, but also cell therapies, gene therapies and biologics, said Greg Kunst, chief executive officer of Aurion Biotech.
  • Dr. Drago joins Aurion Biotech from Biogen, where she led the regulatory team responsible for development products in the United States.
  • The Aurion Biotech team is preparing for clinical trials in the U.S. To learn more about Aurion Biotech, a division of CorneaGen Inc., visit www.aurionbiotech.com .